Ads
related to: belimumab in lupus nephritis- BENLYSTA Dosing Options
Consider Her Schedule And Needs.
Discover The Option That Fits Her.
- What About BENLYSTA?
Could BENLYSTA Be Another Option?
See the Data, Dosing & Resources.
- BENLYSTA Video Library
See Video Stories From Peers &
Dig Into BENLYSTA Patient Profiles.
- BENLYSTA Safety Profile
What Your Patients May Experience.
Learn About Possible Side Effects.
- BENLYSTA Resource Center
Discover A Library Of Resources
Designed To Inform You. Learn More.
- But Why BENLYSTA?
See Clinical Trial Results & More
To Explore BENLYSTA For Yourself.
- BENLYSTA Dosing Options
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
Belimumab: GlaxoSmithKline: active lupus nephritis [1] Osimertinib: AstraZeneca: adjuvant therapy after tumor resection in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations Ansuvimab: Ridgeback Biotherapeutics: Ebola Zaire
Lupus nephritis is an inflammation of the kidneys caused by systemic lupus erythematosus (SLE) and childhood-onset systemic lupus erythematosus which is a more severe form of SLE that develops in children up to 18 years old; both are autoimmune diseases.
Pharmaceutical maker GlaxoSmithKline will begin a phase 3 clinical trial to judge lupus medication Benlysta's effectiveness in treating patients with ANCA-positive vasculitis. The trial, which ...
Lupus nephritis: Kidneys: Anti-dsDNA, Anti-Sm, Anti-nuclear antibodies Confirmed Up to 60% of those with Lupus [49] Interstitial nephritis: Kidneys: Various autoantibodies Probable Varies widely, often drug-induced [50] Interstitial cystitis: Bladder: Anti-urothelial and anti-nuclear antibodies Probable 100-450 per 100,000 women, less common in ...
Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus ...
Ads
related to: belimumab in lupus nephritis